Mafalda Oliveira on Muck Rack

Mafalda Oliveira

As seen in: Nature, The Lancet, Dialnet - Universidad de La Rioja, Cancer Discovery, RAC 1, Future Medicine, ONCOLOGY journal, OncLive, Salud Ediciones, Cancer Treatment Reviews and

Get in touch with Mafalda

Contact Mafalda, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

Clinical audit in improving the quality of care for people with feeding ostomy

|
By Bárbara Costa, Mafalda Oliveira, Ana Maria Reis
| Dialnet - Universidad de La Rioja
español Introducción: La provisión de cuidados de enfermería de alta calidad a personas con ostomía alimentaria es un desafío clínico que requiere prácticas sistematizadas, formación continua y seguimiento de los resultados. La auditoría clínica es una estrategia estructurada para la evaluación y mejora continua de la calidad de la atención.
Open in Who Shared Issue with article?

Exploiting androgen receptor agonism as a treatment strategy in estrogen receptor-positive metastatic breast cancer

|
By Laia Monserrat, Cristina E. Molina, Andreu Òdena, Irene Agustí-Barea, Cristina Viaplana, Aerica Nagornyuk, Marta Guzman, Olga Rodriguez, Fara Brasó-Maristany, Eduardo García-Galea, Rodrigo Dienstmann, Motoki Takaku, Aleix Prat, Sarat Chandarlapaty, Julia Ponomarenko, Cristina Saura, Mafalda Oliveira, Lara Nonell, Meritxell Bellet, Violeta Serra, Judith García-García, Taras Yuziv Duda, Gilles Flamen, Ruth Maldonado-Padrol, Claudia Yáñez-Bartolomé, Flaminia Pedretti, Guillermo P. Vicent
| Nature Verified
Abstract The androgen receptor (AR) is expressed in 75% of estrogen receptor-positive (ER+) breast cancers (BC). Selective AR modulators (SARMs), like EP0062, present a promising therapeutic strategy for ER + BC, particularly in patients who cannot tolerate endocrine therapy (ET) or whose tumors have developed resistance. We aimed to study the antitumor activity of EP0062 in ER+ patient-derived xenograft (PDX) models.
Open in Who Shared Issue with article?

Mafalda Oliveira

|
By Mafalda Oliveira
| ONCOLOGY journal Verified
Articles by Mafalda Oliveira 131 Primary Results From ASCENT-03: A Randomized Phase 3 Study of Sacituzumab Govitecan (SG) vs Chemotherapy (Chemo) in Patients (pts) With Previously Untreated Advanced Triple-Negative Breast Cancer (TNBC) Who Are Unable to Receive PD-(L)1 Inhibitors (PD-[L]1i) ByJavier Cortés, MD,Aditya Bardia, MD, MPH, FASCO,Kevin Punie,Carlos Barrios,Sara A. Hurvitz, MD,Andreas Schneeweiss, MD,Joohyuk Sohn,Eriko Tokunaga,Adam M.
Open in Who Shared View Duplicates (3) Issue with article?
See all 25 licensed articles (26 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified